Cisplatin-induced hearing loss: Influence of the mode of drug administration in the guinea pig

Hearing Research

Volumn 140, Issue 1-2, 2000, Pages 38-44

  Ekborn, A ^a   Laurell, G ^a   Andersson, A ^b   Wallin, I ^b   Eksborg, S ^b   Ehrsson, H ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cisplatin; Nephrotoxicity; Ototoxicity; Pharmacokinetics

Indexed keywords

CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EVOKED AUDITORY RESPONSE; GUINEA PIG; HEARING LOSS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AUDITORY THRESHOLD; CISPLATIN; CREATININE; DEAFNESS; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GUINEA PIGS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE;

EID: 0033960541     PISSN: 03785955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5955(99)00190-2     Document Type: Article

References (32)

1. Aamdal S., Fodstad O., Pihl A. Some procedures to reduce cis-platinum toxicity reduce antitumour activity. Cancer Treat. Rev. 14:1987;389-395.
2. Andersson A., Ehrsson H. Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J. Chromatogr. B. 652:1994;203-210.
3. Andersson A., Fagerberg J., Lewensohn R., Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J. Pharm. Sci. 85:1996;824-827.
4. Axdorph U., Laurell G., Björkholm M. Monitoring of hearing during treatment of leukaemia with special reference to the use of amikacin. J. Intern. Med. 233:1993;401-407.
5. Berry J.M., Jacobs C., Sikic B., Halsey J., Borch R.F. Modification of cisplatin toxicity with diethyldithiocarbamate. J. Clin. Oncol. 8:1990;1585-1590.
6. Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.-J., Kuczyk M.A., Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer. 77:1998;1355-1362.
7. Boxenbaum H.G., Riegelman S., Elashoff R.M. Statistical estimation in Pharmacokinetics. J. Pharmacokinet. Biopharm. 2:1974;123-148.
8. Comis R.L. Cisplatin: The future. Semin. Oncol. 21:1994;109-113.
9. Dormans T.P.J., Van Meyel J.J.M., Gerlag P.G.G., Tan Y., Russel F.G.M., Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J. Am. Coll. Cardiol. 28:1996;376-382.
10. Finley R.S., Fortner C.L., Grove W.R. Cisplatin nephrotoxicity: A summary of preventative interventions. Drug Intell. Clin. Pharm. 19:1985;362-367.
11. Fleischmann R.W., Stadnicki S.W., Ethier M.F., Schaeppi U. Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. Toxicol. Appl. Pharmacol. 33:1975;320-332.
12. Forastiere A.A., Belliveau J.F., Goren M.P., Vogel W.C., Posner M.R., O'Leary G.P. Jr. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res. 48:1988;3869-3874.
13. Gandara D.R., Wiebe V.J., Perez E.A., Makuch R.W., DeGregorio M.W. Cisplatin rescue therapy: Experience with sodium thiosulfate, WR2721 and diethyldithiocarbamate. Crit. Rev. Oncol. Hematol. 10:1990;353-365.
14. Hainsworth J.D., Grosh W.W., Burnett L.S., Jones H.W. III, Wolff S.N., Greco F.A. Advanced ovarian cancer: Long term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann. Intern. Med. 108:1988;165-170.
15. Hayes D.M., Cvitkovic E., Golbey R.B., Scheiner E., Helson L., Krakoff I.H. High dose cis-platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer. 39:1977;1372-1381.
16. 2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother. Pharmacol. 29:1991;29-32.
17. Laurell G., Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear. Res. 38:1989;27-34.
18. Laurell G., Andersson A., Engström B., Ehrsson H. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother. Pharmacol. 36:1995;83-86.
19. Lokich J.J. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion. Cancer Treat. Rep. 64:1980;905-908.
20. Marty M. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur. J. Cancer Clin. Oncol. 25:1989;41-45.
21. Muggia F.M. Testicular cancer and the legacy of chemotherapy. Cancer Chemother. Pharmacol. 15:1985;1-5.
22. Nagai N., Ogata H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother. Pharmacol. 40:1997;11-18.
23. Piel I., Meyer D., Perlia C., Wolte V. Effects of cisplatin on hearing function in man. Cancer Chemother. Rep. 58:1974;871-875.
24. Reddel R.R., Kefford R.F., Grant J.M., Coates A.S., Fox R.M., Tattersall M.H.N. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat. Rep. 66:1982;19-23.
25. Reece P.A., Stafford I., Davy M., Morris R., Freeman S. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother. Pharmacol. 24:1989;256-260.
26. Rybak L.P., Ravi R., Somani S.M. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fundam. Appl. Toxicol. 26:1995;293-300.
27. Salem P., Khalyl M., Jabboury K., Hashimi L. Cis-diamminedichloroplatinum(II) by 5-day continous infusion: A new dose schedule with minimal toxicity. Cancer. 53:1984;837-840.
28. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 54:1984;1269-1275.
29. Vargo, D.L., 1984. Non Parametric Statistics. Quick and Easy on the HP41. Edu Calc Publications, CA.
30. Vermorken J.B., Kapteijn T.S., Hart A.A.M., Pinedo H.M. Ototoxicity of cis-diamminedichloroplatinum(II): Influence of dose, schedule and mode of administration. Eur. J. Cancer Clin. Oncol. 19:1983;53-58.
31. Yachnin J.R., Wallin I., Lewensohn R., Sirzén F., Ehrsson H. The kinetics and cytotoxicity of cisplatin and its monohydrated complex. Cancer Lett. 132:1998;175-180.
32. Zunino F., Pratesi G., Micheloni A., Cavalletti E., Sala F., Tofanetti O. Protective effect of reduced glutathione against cisplatin induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem. Biol. Interact. 70:1989;89-101.